MYK 461

Drug Profile

MYK 461

Alternative Names: MYK461; SAR-439152

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator MyoKardia
  • Class Cardiovascular therapies
  • Mechanism of Action Myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Hypertrophic cardiomyopathy in USA (PO) (NCT02842242)
  • 11 Jul 2016 Top-line pharmacodynamics and adverse events data from a phase I trials in Hypertrophic cardiomyopathy released by MyoKardia
  • 30 Apr 2016 MYK 461 receives Orphan Drug status for Hypertrophic cardiomyopathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top